Insider Selling: Pfizer, Inc. (PFE) Insider Sells $249,900.00 in Stock
Pfizer, Inc. (NYSE:PFE) insider Alexander R. Mackenzie sold 7,350 shares of the company’s stock in a transaction on Friday, September 1st. The stock was sold at an average price of $34.00, for a total value of $249,900.00. Following the transaction, the insider now owns 124,774 shares in the company, valued at $4,242,316. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Pfizer, Inc. (NYSE:PFE) opened at 33.99 on Friday. The firm’s 50 day moving average price is $33.34 and its 200 day moving average price is $33.48. Pfizer, Inc. has a one year low of $29.83 and a one year high of $34.75. The stock has a market cap of $202.15 billion, a price-to-earnings ratio of 24.86 and a beta of 1.00.
Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.02. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The firm had revenue of $12.90 billion for the quarter, compared to analyst estimates of $13.08 billion. During the same quarter in the previous year, the business posted $0.64 EPS. The firm’s revenue was down 1.9% compared to the same quarter last year. Equities analysts forecast that Pfizer, Inc. will post $2.56 earnings per share for the current year.
The business also recently announced a quarterly dividend, which was paid on Friday, September 1st. Stockholders of record on Friday, August 4th were paid a $0.32 dividend. The ex-dividend date of this dividend was Wednesday, August 2nd. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.77%. Pfizer’s dividend payout ratio (DPR) is presently 94.12%.
COPYRIGHT VIOLATION NOTICE: This news story was originally published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://theolympiareport.com/2017/09/08/insider-selling-pfizer-inc-pfe-insider-sells-249900-00-in-stock.html.
A number of research firms have commented on PFE. Jefferies Group LLC set a $35.00 price target on Pfizer and gave the stock a “neutral” rating in a research note on Wednesday, August 2nd. Berenberg Bank set a $39.00 price target on Pfizer and gave the stock a “neutral” rating in a research note on Tuesday, August 1st. Morgan Stanley restated a “neutral” rating and set a $35.00 price target (down from $38.00) on shares of Pfizer in a research note on Monday, June 12th. Citigroup Inc. cut Pfizer from a “neutral” rating to a “sell” rating and reduced their price objective for the company from $38.00 to $31.00 in a research note on Tuesday, May 16th. Finally, Zacks Investment Research upgraded Pfizer from a “sell” rating to a “hold” rating in a research note on Friday, July 14th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $37.61.
Several institutional investors have recently modified their holdings of the company. Vanguard Group Inc. raised its stake in shares of Pfizer by 2.3% in the 2nd quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock valued at $14,062,088,000 after purchasing an additional 9,239,499 shares in the last quarter. Franklin Resources Inc. raised its stake in shares of Pfizer by 0.9% in the 2nd quarter. Franklin Resources Inc. now owns 46,167,213 shares of the biopharmaceutical company’s stock valued at $1,550,754,000 after purchasing an additional 389,629 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Pfizer by 4.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 44,286,544 shares of the biopharmaceutical company’s stock valued at $1,487,617,000 after purchasing an additional 2,028,313 shares in the last quarter. Fisher Asset Management LLC raised its stake in shares of Pfizer by 3.9% in the 2nd quarter. Fisher Asset Management LLC now owns 34,035,362 shares of the biopharmaceutical company’s stock valued at $1,143,248,000 after purchasing an additional 1,275,832 shares in the last quarter. Finally, LSV Asset Management raised its stake in shares of Pfizer by 0.6% in the 2nd quarter. LSV Asset Management now owns 33,275,572 shares of the biopharmaceutical company’s stock valued at $1,117,726,000 after purchasing an additional 199,100 shares in the last quarter. Institutional investors and hedge funds own 69.09% of the company’s stock.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.